Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6T4N

Human Carbonic anhydrase II bound by 2,4,6-trimethylbenzenesulfonamide

Summary for 6T4N
Entry DOI10.2210/pdb6t4n/pdb
Descriptorcarbonic anhydrase 2, ZINC ION, 2,4,6-trimethylbenzenesulfonamide, ... (7 entities in total)
Functional Keywordsdrug design, carbonic anhydrase, benzenesulfonamide, metal-binding, lyase-lyase inhibitor complex, lyase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight29925.23
Authors
Smirnov, A.,Manakova, E.,Grazulis, S. (deposition date: 2019-10-14, release date: 2020-10-14, Last modification date: 2024-01-24)
Primary citationDudutiene, V.,Zubriene, A.,Kairys, V.,Smirnov, A.,Smirnoviene, J.,Leitans, J.,Kazaks, A.,Tars, K.,Manakova, L.,Grazulis, S.,Matulis, D.
Isoform-Selective Enzyme Inhibitors by Exploring Pocket Size According to the Lock-and-Key Principle.
Biophys.J., 119:1513-1524, 2020
Cited by
PubMed Abstract: In the design of high-affinity and enzyme isoform-selective inhibitors, we applied an approach of augmenting the substituents attached to the benzenesulfonamide scaffold in three ways, namely, substitutions at the 3,5- or 2,4,6-positions or expansion of the condensed ring system. The increased size of the substituents determined the spatial limitations of the active sites of the 12 catalytically active human carbonic anhydrase (CA) isoforms until no binding was observed because of the inability of the compounds to fit in the active site. This approach led to the discovery of high-affinity and high-selectivity compounds for the anticancer target CA IX and antiobesity target CA VB. The x-ray crystallographic structures of compounds bound to CA IX showed the positions of the bound compounds, whereas computational modeling confirmed that steric clashes prevent the binding of these compounds to other isoforms and thus avoid undesired side effects. Such an approach, based on the Lock-and-Key principle, could be used for the development of enzyme-specific drug candidate compounds.
PubMed: 32971003
DOI: 10.1016/j.bpj.2020.08.037
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.4 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon